Evidence map›Paper›PMID 34396470›Full record

ReviewAnalytical and bioanalytical chemistry2021

A review of biosensors for the detection of B-type natriuretic peptide as an important cardiovascular biomarker.

Meysam Gachpazan, Arash Mohammadinejad, Amin Saeidinia, Hamid Reza Rahimi, Majid Ghayour-Mobarhan, Farveh Vakilian, Majid Rezayi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 33 citations in OpenAlex.

  1. Wearable Flexible Sensors for Cardiovascular Disease Monitoring.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Development of biosensors for detection of fibrinogen: a review.Analytical and bioanalytical chemistry · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Meysam Gachpazan *Medical Genetics Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Arash Mohammadinejad *Department of Medical Biotechnology and Nanotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Amin SaeidiniaPediatric Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Hamid Reza RahimiVascular and Endovascular Surgery Research Center, Alavi Hospital, Mashhad University of Medical Sciences, Mashhad, 9177899191, Iran.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran.
Farveh VakilianClinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 9176699199, Iran.
Majid RezayiDepartment of Medical Biotechnology and Nanotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran. Rezaeimj@mums.ac.ir.
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart disease, as the most serious threat to human health globally, is responsible for rising mortality rates, largely due to lifestyle and diet. Unfortunately, the main problem for patients at high risk of heart disease is the validation of prognostic tests. To this end, the detection of cardiovascular biomarkers has been employed to obtain pathological and physiological information in order to improve prognosis and early-stage diagnosis of chronic heart failure. Short-term changes in B-type natriuretic peptide are known as a standard and important biomarker for diagnosis of heart failure. The most important problem for detection is low concentration and short half-life in the blood. The normal concentration of BNP in blood is less than 7 nM (25 pg/mL), which increases significantly to more than 80 pg/mL. Therefore, the development of new biosensors with better sensitivity, detection limit, and dynamic range than current commercial kits is urgently needed. This review classifies the biosensors designed for detection of BNP into electrochemical, optical, microfluidic, and lateral-flow immunoassay techniques. The review clearly demonstrates that a variety of immunoassay, aptasensor, enzymatic and catalytic nanomaterials, and fluorophores have been successfully employed for detection of BNP at low attomolar ranges. Dtection of B-type natriuretic peptide with biosensors.

Indexed as

Biosensing TechniquesBiomarkersCardiovascular DiseasesHumansLimit of DetectionNatriuretic Peptide, BrainBiomarkersNatriuretic Peptide, BrainBiomarkerBiosensorB-type natriuretic peptideHeart failure

Identifiers

PMID34396470
OpenAlexW3195607565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.